DVAX: William Blair analysts predict restricted-label approval with price target of $5. http://seekingalpha.com/article/1109311-william-blair-analysts-are-gaining-comfort-ahead-of-dynavax-s-heplisav-pdufa?source=feed FWIW, I agree.